Literature DB >> 11672545

Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells.

S M Varga1, X Wang, R M Welsh, T J Braciale.   

Abstract

Vaccination with the respiratory syncytial virus (RSV) attachment (G) protein results in immune-mediated lung injury after natural RSV infection with pathogenic features characteristic of an exaggerated Th2 response. Here we demonstrate that approximately half of the CD4(+) T cells infiltrating the lungs of G-primed mice utilize a single V beta gene (V beta 14) with remarkably limited CDR3 diversity. Furthermore, elimination of these V beta 14-bearing CD4(+) T cells in vivo abolishes the type 2-like pulmonary injury. These results suggest that a novel subset of CD4(+) T cells may be crucial in the development of pathology during human RSV infection and that genetic or environmental factors prior to or at the time of G antigen exposure may affect the commitment of this discrete antigen-specific T cell subset to Th2 differentiation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672545     DOI: 10.1016/s1074-7613(01)00209-6

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  73 in total

Review 1.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.

Authors:  Luis Martinez-Sobrido; Negin Gitiban; Ana Fernandez-Sesma; Jerome Cros; Sara E Mertz; Nancy A Jewell; Sue Hammond; Emilio Flano; Russell K Durbin; Adolfo García-Sastre; Joan E Durbin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen.

Authors:  H Höhn; C Neukirch; K Freitag; A Necker; W Hitzler; B Seliger; M J Maeurer
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

5.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

6.  Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry.

Authors:  Whitney W Stevens; Taeg S Kim; Lindsey M Pujanauski; Xueli Hao; Thomas J Braciale
Journal:  J Immunol Methods       Date:  2007-08-08       Impact factor: 2.303

7.  Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.

Authors:  Susan M Bueno; Pablo A González; Kelly M Cautivo; Jorge E Mora; Eduardo D Leiva; Hugo E Tobar; Glenn J Fennelly; Eliseo A Eugenin; William R Jacobs; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

8.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

9.  Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.

Authors:  Eun Kim; Kaori Okada; Judy A Beeler; Roberta L Crim; Pedro A Piedra; Brian E Gilbert; Andrea Gambotto
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

10.  Proliferative expansion and acquisition of effector activity by memory CD4+ T cells in the lungs following pulmonary virus infection.

Authors:  Erika L Wissinger; Whitney W Stevens; Steven M Varga; Thomas J Braciale
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.